biostudies-literatureDeng CNational High Level Hospital Clinical Research FundingBeijing Key Project of Coordination of Chinese and Western Medicine For Major Refractory DiseasesNational Natural Science Foundation of ChinaCapital’s Funds for Health Improvement and ResearchCapital's Funds for Health Improvement and ResearchElite Medical Professionals Project of China-Japan Friendship Hospital153https://www.ebi.ac.uk/biostudies/studies/S-EPMC11536713biostudies-literatureUnknown19(1)<h4>Background</h4>Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We designed this clinical trial to supply more evidences on the use of SXD as prophylaxis for irinotecan-induced diarrhea, especially for high-risk population predicted by gene testing of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1).<h4>Methods</h4>In this clinical trial, 120 patients with SCLC were recruited from six hospitals in China. They received two cycles of chemotherapy, meanwhile they were randomized to receive SXD or placebo for 14 days of oral administration in each cycle ofChinese medicineEfficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial.PMC1153671382374537NO.ZRJY2023-GG01ShouFa 2018-1-406181904001ShouFa 2018–1-4061No.4 Small Cell Lung CancerDeng CYang GWLou YNZhu SJZhang ZGGe YYang MGao YLiu QJia LQLi QCui HJfalseEfficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial.<h4>Background</h4>Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We designed this clinical trial to supply more evidences on the use of SXD as prophylaxis for irinotecan-induced diarrhea, especially for high-risk population predicted by gene testing of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1).<h4>Methods</h4>In this clinical trial, 120 patients with SCLC were recruited from six hospitals in China. They received two cycles of chemotherapy, meanwhile they were randomized to receive SXD or placebo for 14 days of oral administration in each cycle of2024-01-01T00:00:00Z2024 Nov2025-04-04T03:05:05.435Z2025-04-04T03:05:05.435ZS-EPMC115367133949711610.1186/s13020-024-01025-6